Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
61 Clinical Trials near Missouri
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
UTI Vaccine for Urinary Tract Infections
Lenexa, KansasThe purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 64
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunodeficient, Neurological Disorders, Others
Must Not Be Taking:Antibiotics, Methenamine, D-mannose
448 Participants Needed
Combination Vaccine for Flu and COVID-19
Saint Louis, MissouriThis study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
780 Participants Needed
Personalized Music for Delirium
Saint Louis, MissouriThis is a prospective randomized controlled trial in children 3-9 years of age undergoing myringotomies at Washington University in St. Louis to assess the impact of perioperative personalized music on the incidence of emergence agitation.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:3 - 9
Sex:All
Key Eligibility Criteria
Disqualifiers:Combined Procedures, Lack Of Interest, Others
160 Participants Needed
MET097 for Obesity
Overland Park, KansasThe goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity.
The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET097 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET097 or placebo. In Part C, participants will receive once-weekly doses of MET097 or placebo for 12 weeks, followed by a single dose at 2X or 4X to explore the potential for once-monthly dosing.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 70
Sex:All
262 Participants Needed
Flu Vaccine for Influenza
Kansas City, MissouriThe purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
1158 Participants Needed
Combination Vaccine for COVID-19 and Flu
Creve Coeur, MissouriStudy VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone, rC19 (dose 1) alone, and IIV-HD and rC19 (dose 1) (coadministered in opposite arms).
Placebo will be coadministered in the IIV-HD alone, rC19 (dose 1) alone, and IIV-HD + rC19 study groups to control for the number of injections and to maintain observer-blinding.
Thus, each participant will receive two injections at enrollment, one in each deltoid muscle.
Study details include:
* The study duration will be approximately 12 months
* Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on D01
* Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose)
* The visit frequency will be D01, D09 (telephone call), D30, D182 (telephone call), and D366 (telephone call)
Number of Participants:
Approximately 980 participants are expected to be randomized.
Stay on current meds
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Bleeding Disorder, Stroke, Others
Must Not Be Taking:Immunosuppressants, Anticoagulants
980 Participants Needed
Flu and COVID-19 Vaccines for Virus Protection
Springfield, MissouriThis study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
1353 Participants Needed
BMS-986470 for Sickle Cell Disease
Lenexa, KansasThe purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe VOCs, Acute Chest Syndrome, Others
Must Be Taking:Hydroxyurea
184 Participants Needed
Flu Vaccine for Adults
Kansas City, MissouriThis trial is testing new mRNA flu vaccines in adults aged 18 and older. The vaccines work by using genetic instructions to help the body recognize and fight the flu virus. The study aims to see if these new vaccines are safe and effective. The first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses were evaluated for safety and effectiveness over a period of several years.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
910 Participants Needed
Sleep Health Enhancement for Middle-Aged Adults
Kansas City, KansasDespite the strong links between sleep and AD, a sleep health enhancement has yet to be targeted in mid-life adults (45-64 years old) to delay or prevent AD. An intervention aimed at enhancing sleep health is a critical opportunity for primary prevention to potentially delay the onset of AD. The objective of the proposed study is to develop and assess the feasibility, acceptability, and treatment effect of a comprehensive sleep health intervention (SHI) on improving sleep health in mid-life adults
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:45 - 64
Sex:All
Key Eligibility Criteria
Disqualifiers:Sleep Disorders, Severe Depression, Anxiety, Others
Must Not Be Taking:Sleep Medications
40 Participants Needed
RSV/hMPV Vaccine for Respiratory Infections
Kansas City, MissouriThis trial is testing a new vaccine for lung infections caused by RSV and hMPV in adults aged 60 and older. The vaccine aims to help the immune system recognize and fight these viruses.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:60+
Sex:All
646 Participants Needed
mRNA Vaccines for Norovirus
Lenexa, KansasThis trial tests the safety and immune response of two experimental mRNA vaccines, mRNA-1403 and mRNA-1405, in healthy adults. The vaccines help the body learn to fight a virus by giving it a practice run without causing illness.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 80
Sex:All
1285 Participants Needed
Investigational Monkeypox Vaccines for Monkeypox
Kansas City, MissouriThis is a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox (mpox).
This study started with substudy A (SSA) and substudy B (SSB) for which recruitment has been completed. A Substudy C (SSC) was planned, but the sponsor decided not to conduct it. This study will therefore continue with substudy D (SSD).
In SSA and SSB, dosing started with an initial sentinel group, followed by the expansion cohort.
This study was initially planned to investigate two vaccine candidates (the quadrivalent BNT166a and the trivalent BNT166c). The sponsor decided to not activate the groups with BNT166c.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Mpox, Smallpox, Diabetes, Hypertension, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids
96 Participants Needed
mRNA Vaccines for Lyme Disease
Lenexa, KansasThis trial is testing two different vaccines for Lyme disease in healthy adults. One vaccine targets seven parts of the bacteria, and the other targets just one. The vaccines use mRNA to teach the immune system to recognize and fight the bacteria.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 70
Sex:All
807 Participants Needed
C. difficile Vaccine for C. difficile Infection
Saint Louis, MissouriAn antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff). Three new formulations of the C. diff vaccine will be used in this study, in addition to a C. diff vaccine formulation that has been studied in previous clinical trials.
The purpose of this study is to understand if giving the new C. diff vaccine formulations helps people make as many antibodies as giving the previously studied C. diff vaccine formulation.
The study is divided into 2 phases.
Phase 1 will evaluate 3 new formulations of the C. diff vaccine and 2 dosing schedules spread out over 2 months or 6 months.
The Phase 1 portion of the study is seeking participants:
* who are healthy adults of 65 to 84 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
All participants in Phase 1 will receive study injections with active vaccine or placebo at each vaccination visit, depending on the vaccine group to which they are assigned. A placebo does not contain any active ingredients. Participants in Phase 1 will attend at least 9 study visits and will take part in the study for approximately 18 months. Based on the results of Phase 1, 1 or 2 of the new C. diff vaccine formulations will be chosen for further study in Phase 2.
Phase 2 will evaluate the safety and effects of the new C. diff vaccine formulation(s) chosen in Phase 1.
The Phase 2 portion of the study is seeking participants:
* who are healthy adults ≥65 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
Phase 2 participants will receive active C. diff vaccine or placebo at each vaccination visit. Participants in Phase 2 will attend at least 6 and up to 12 study visits and will take part in the study for up to 4 years.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:65 - 84
Sex:All
689 Participants Needed
ALN-KHK for Type 2 Diabetes
Overland Park, KansasThis trial is testing a new drug called ALN-KHK to see how safe it is and how the body processes it. They are also testing another drug called KHK to check its safety and effectiveness. The study targets patients who might benefit from these drugs, aiming to understand their safety and how they work in the body.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
49 Participants Needed
BMF-219 for Type 2 Diabetes
Saint Louis, MissouriThis trial tests a new pill called BMF-219 that targets a protein named menin. It includes healthy adults and those with Type 2 Diabetes to see if it helps control blood sugar levels.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
414 Participants Needed
Flu and COVID-19 Vaccines for Coronavirus and Influenza
Chesterfield, MissouriThe purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together.
This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
2050 Participants Needed
64Cu-DOTA-ECL1i for Heart Attack
Saint Louis, MissouriTo determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the cellular level in the myocardium for individuals who have suffered a heart attack or who have other inflammatory heart disease.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:21 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Hypertension, Heart Failure, Others
Must Not Be Taking:Prescription Medications
90 Participants Needed
VK4-116 for Opioid Use Disorder
Overland Park, KansasThis first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:All
48 Participants Needed
Ceftibuten-ledaborbactam Etzadroxil for Healthy Subjects
Lenexa, KansasThis is a Phase 1, open-label, two-part, study in approximately 46 healthy adult participants between 18 and 55 years of age (both inclusive) (at least 16 participants in Part 1 and up to 30 participants in Part 2). The study will be conducted at one clinical site in the United States. Participants in Part 1 and Part 2 may be conducted in parallel. The duration of an individual participation will be approximately 46 days for Part 1 and 43 days for Part 2. All participants will be screened within 28 days prior to dosing. They will be admitted to the clinical research unit (CRU) the day prior to dosing and will remain in the CRU until the end of the PK sample collection period. All participants will return to the clinic for follow-up assessments 7 days ± 1 day after the last dose of study intervention.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
46 Participants Needed
mRNA Vaccine for RSV
Lenexa, KansasThe purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:All
210 Participants Needed
Orforglipron for Obesity
Overland Park, KansasThe main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated.
The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Cardiovascular, Psychiatric, Others
508 Participants Needed
Long-Acting VH4524184 for HIV
Lenexa, KansasThe purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Liver Disease, Cardiac Disease, Cancer, Others
Must Not Be Taking:Anticoagulants, Enzyme Inducers, Others
72 Participants Needed
Negative Pressure Therapy for Surgical Wounds
Kansas City, KansasThe goal of this clinical trial is to evaluate the safety of the investigational device, Regenn® Negative Pressure Therapy System (Regenn® Therapy), a form of Negative Pressure Wound Therapy (NPWT), in the post-operative surgical wounds of patients undergoing lumbar spinal fusion surgeries. The main questions the study aims to answer are:
* The device-related serious adverse event rate.
* Patient post-operative pain as assessed using a validated pain measurement scoring system.
* The number and type of adverse events.
* The rate of delayed seroma formation.
Participants will
* Be screened for their suitability to participate in the investigational study using questions about their health, medical history, and current medications.
* Undergo a physical exam, an assessment of patient vital signs and routine blood analyses.
* Complete an Informed Consent Form if selected to participate in the investigational study.
* Be randomly assigned to the different study arms.
* Not change the operation of their respective device or to disturb components of their device.
* Notify their surgeon or designated healthcare provider should they have any questions or encounter any issues with their device.
* Attend two post-operative visits at approximately one month and three months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Hepatic Insufficiency, Autoimmune Diseases, Others
Must Not Be Taking:Steroids, Immunosuppressants
30 Participants Needed
SRF114 for Solid Tumors
Saint Louis, MissouriThis is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Nasopharyngeal Carcinoma, Others
Must Not Be Taking:Anti-CCR8, Anticoagulants
87 Participants Needed
Oral Dexmedetomidine for Pediatric Anesthesia
Kansas City, MissouriThe objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:3 - 6
Sex:All
18 Participants Needed
VLP Peanut for Peanut Allergy
Saint Louis, MissouriThis phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Severe Asthma, Anaphylaxis, Others
46 Participants Needed
Tau Radioligand Imaging for Alzheimer's Disease
Saint Louis, MissouriThis is an open label study to compare three new generation TAU radioligands, 18F-RO948 (formerly known as 18F-6958948), 18F-MK6240, and \[18F\]GTP1for imaging of taupathy and demonstrate their absence of off-target binding in patients with Alzheimer disease (AD) and older healthy controls (OC). The study will directly compare AD and OC with these three next-generation TAU radioligands and compare each of them with historical data of the current most widely used first generation radioligand, 18F-AV1451. Upto38 (30 AD (Amyloid +)and 8 OC (Amyloid -), matched for age and sex with A+ subjects) male and female subjects aged 50-100 will be enrolled in this study protocol: up to 8 for Cohort 1, up to 8 for Cohort 2, and up to 22 for Cohort 3. The study consists of three cohorts: Cohort 1: Up to8 AD subjects (A+; CDR 0.5 and 1)will receive two PET scans in random order, with receiving either18F-RO948 or18F-MK6240 at the first scan. A third scan with 18F-GTP1is possible, depending on timing and radiotracer availability Cohort 2:Up to8 OC (A-; CDR=0)subjects will receive two PET scans in random order, with receiving either18F-RO948or 18F-MK6240 at the first scan. A third scan with 18F-GTP1is possible, depending on timing and radiotracer availability Cohort 3:Up to 22 (A+; CDR = 0, .5 and 1) subjects will receive three PET scans in random order, with receiving 18F-RO94818F-MK6240 or18F-GTP1at the first scan. Efforts will be made to include about 1/3 CDR = 0, 1/3 CDR .5, and 1/3 CDR 1 in Cohort 3.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50 - 100
Sex:All
Key Eligibility Criteria
Disqualifiers:Stroke, Traumatic Brain Injury, HIV, Others
Must Not Be Taking:Anticoagulants, Investigational Drugs
38 Participants Needed
Sirolimus for Brain Health
Columbia, MissouriAlzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure. Sirolimus is an FDA-approved medication which may improve the blood flow to the brain.
Part I: This study is designed to see if sirolimus treatment improves MRI blood flow to the brain in individuals with and without a genetic predisposition to Alzheimer's disease. Part I of this study is complete and no longer enrolling participants.
Part II: Ongoing research will expand the genetic predisposition cohort and further explore the drug's impact on the lung perfusion via hyperpolarized xenon-129 gas MRI and the brain-vascular connection. Only subjects who are APOE4 carriers will be enrolled in Part II.
Hyperpolarized xenon-129 gas MRI is a non-invasive technique in which a subject inhales a bolus of hyperpolarized xenon-129 gas which can be directly imaged by the MRI as it physiologically distributes itself throughout the lung interior and within tissue and red blood cells. It thus allows for direct imaging and quantification of regional lung function: ventilation, gas-exchange, and perfusion. The relationship between pulmonary vascular function and brain perfusion is largely unstudied. We hope to investigate the relationship between pulmonary vascular function and cerebral blood flow by quantifying both lung and brain perfusion before and after the administration of Sirolimus.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:45 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Pulmonary Disease, Heart Failure, Others
Must Not Be Taking:Antiplatelets, Anticoagulants, Immunosuppressants, Others
205 Participants Needed
Page 1 of 3+
Frequently Asked Questions
How much do clinical trials in Missouri pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do clinical trials in Missouri work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Missouri 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Missouri is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Missouri several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a medical study in Missouri ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest clinical trials in Missouri ?
Most recently, we added VK4-116 for Opioid Use Disorder, Oral Dexmedetomidine for Pediatric Anesthesia and BMS-986460 for Healthy Subjects to the Power online platform.